Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Adjunctive daptomycin confers no benefit in MSSA bloodstream infections

11 Aug 2020

For patients with methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs), the use of daptomycin as an adjunct to standard treatment does not help shorten the duration of bacteraemia and, hence, should be done away with, as suggested in a study.

A total of 115 adult patients treated with either cefazolin or cloxacillin were randomized to undergo a 5-day course of adjunctive daptomycin or placebo. Of these, 104 patients (median age, 67 years; 34.5 percent female) were included in the final analysis.

Endovascular infection (39.4 percent) was the most common cause of bacteraemia, followed by skin and soft tissue infections (24.0 percent), osteomyelitis (7.7 percent), and pneumonia (6.7 percent). Most patients were treated with cefazolin (73.1 percent) and had a complicated bloodstream infection (78.8 percent).

There was no significant difference in the primary outcome of duration of MSSA BSI between daptomycin and placebo (median, 2.04 vs 1.65 days, respectively; absolute difference, 0.39 days; p=0.40). Likewise, adjunctive daptomycin did not result in substantial reduction in 90-day mortality compared with placebo (18.9 percent vs 17.7 percent; p=1.0).

Daptomycin was well tolerated, and no serious adverse events were reported. The proportion of patients who developed renal failure, hepatotoxicity, or rhabdomyolysis was similar in the active treatment and placebo groups.

The findings oppose evidence from in vitro studies suggesting that adding daptomycin to an anti-staphylococcal beta-lactam (ASBL) results in synergistic activity against S. aureus, researchers said. Instead, the combination yields null effects in the management of patients with MSSA BSIs. [Antimicrob Agents Chemother 2004;48:2871-2875]

Therefore, daptomycin should not be added to ASBL in this population, as indicated in current treatment guidelines, they added. [JAMA 2018;320:1249-1258; JAMA 2014;312:1330-1341]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.